• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血友病犬对桥接抗凝中和剂的反应。

Hemophilic dogs response to Bridge anticoagulant neutralizing agent.

作者信息

Nour-Eldin F

出版信息

Transfusion. 1983 Nov-Dec;23(6):533-4. doi: 10.1046/j.1537-2995.1983.23684074281.x.

DOI:10.1046/j.1537-2995.1983.23684074281.x
PMID:6417849
Abstract

When Bridge anticoagulant neutralizing agent, prepared by column fractionation, was infused with factor VIII concentrate into a hemophilic dog, the apparent level of circulating factor VIII was markedly increased. Material isolated from 30 ml donor plasma raised the level of factor VIII nearly three-fold, during the first post-transfusion hour. This was achieved without shortening the period during which a hemostatically-effective level of factor VIII was maintained. The same dose also reduced the amount of factor VIII required for prompt and successful hemostasis after standardized template gingival biopsy.

摘要

当通过柱分级分离制备的桥梁抗凝中和剂与因子VIII浓缩物一起注入一只血友病犬体内时,循环中因子VIII的表观水平显著升高。从30毫升供体血浆中分离出的物质在输血后的第一个小时内使因子VIII水平提高了近三倍。在保持因子VIII止血有效水平的时间段不缩短的情况下实现了这一点。相同剂量还减少了标准化模板牙龈活检后迅速成功止血所需的因子VIII量。

相似文献

1
Hemophilic dogs response to Bridge anticoagulant neutralizing agent.血友病犬对桥接抗凝中和剂的反应。
Transfusion. 1983 Nov-Dec;23(6):533-4. doi: 10.1046/j.1537-2995.1983.23684074281.x.
2
[Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].[活化凝血酶原复合物(FEIBA)对伴有Ⅷ或Ⅸ因子抑制物的血友病患者的临床疗效]
Nihon Ketsueki Gakkai Zasshi. 1982 Sep;45(5):987-92.
3
[Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
Nouv Presse Med. 1975 Oct 25;4(36):2571-4.
4
Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
Thromb Res. 1981;22(1-2):177-84. doi: 10.1016/0049-3848(81)90319-4.
5
The effect of adrenaline infusions on blood coagulation in normal and haemophilia B dogs.肾上腺素输注对正常犬和B型血友病犬血液凝固的影响。
Thromb Diath Haemorrh. 1966 May 15;15(3):349-64.
6
Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions.用于评估血浆蛋白组分治疗效果的血友病犬模型
Blood. 1981 Nov;58(5):868-72.
7
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.采用群体药代动力学方法评估和解读甲型或乙型血友病个体患者的药代动力学特征:国际血栓与止血学会科学和标准化委员会的通讯
J Thromb Haemost. 2017 Dec;15(12):2461-2465. doi: 10.1111/jth.13867. Epub 2017 Nov 9.
8
Prothrombin complex concentrates for clinical use.临床用凝血酶原复合物浓缩剂。
Vox Sang. 1981 Nov-Dec;41(5-6):257-73. doi: 10.1111/j.1423-0410.1981.tb01048.x.
9
Factor VIII: maximal benefit?凝血因子VIII:最大益处?
Eur J Med. 1992 Apr;1(1):55-7.
10
Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.
J Pediatr. 1976 Feb;88(2):200-5. doi: 10.1016/s0022-3476(76)80982-1.